Vaxart Stock Price

-0.04 (-3.23%)
Upgrade to Real-Time
Regular Market
Volume 217,392
Bid Price 1.20
Ask Price 1.21
News -
Day High 1.25


52 Week Range


Day Low 1.20
Company Name Stock Ticker Symbol Market Type
Vaxart Inc VXRT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -3.23% 1.20 09:54:18
Open Price Low Price High Price Close Price Prev Close
1.24 1.20 1.25 1.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
928 217,392 $ 1.23 $ 266,568 - 1.17 - 8.13
Last Trade Time Type Quantity Stock Price Currency
09:54:18 184 $ 1.20 USD


Draw Mode:

Vaxart Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 157.50M 131.25M 117.29M $ 892.00k $ - -0.58 -1.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 428.55k 2.50%

more financials information »

Vaxart News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VXRT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.341.381.171.261,922,033-0.14-10.45%
1 Month1.611.7251.171.453,110,742-0.41-25.47%
3 Months2.722.93591.171.873,028,895-1.52-55.88%
6 Months3.724.6151.172.762,810,540-2.52-67.74%
1 Year7.708.131.173.942,839,297-6.50-84.42%
3 Years0.354524.900.28057.429,999,9880.8455238.5%
5 Years7.46924.900.25437.316,247,278-6.27-83.93%

Vaxart Description

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.